{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:03:28Z","timestamp":1740146608746,"version":"3.37.3"},"reference-count":16,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","award":["OUH2017"],"award-info":[{"award-number":["OUH2017"]}],"id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","award":["OUH2017"],"award-info":[{"award-number":["OUH2017"]}],"id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","award":["OUH2017"],"award-info":[{"award-number":["OUH2017"]}],"id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0229469","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T13:57:39Z","timestamp":1582293459000},"page":"e0229469","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9578-7632","authenticated-orcid":true,"given":"Faouzi","family":"Djebbari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faye A.","family":"Sharpley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"McLain-Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6539-4002","authenticated-orcid":true,"given":"Grant","family":"Vallance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toby A.","family":"Eyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaimal","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"pone.0229469.ref001","unstructured":"Cancer Research UK. Cancer statistics: Myeloma incidence statistics. Available from: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma\/incidence. Accessed April 4, 2018"},{"key":"pone.0229469.ref002","first-page":"498","article-title":"Management of multiple myeloma in the newly diagnosed patient","author":"American Society of Hematology","year":"2017","journal-title":"Hematology"},{"key":"pone.0229469.ref003","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"FIRST Trial Team","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"pone.0229469.ref004","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"MM-015 Investigators","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"pone.0229469.ref005","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Alcyone Trial Investigators","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"pone.0229469.ref006","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"MAIA Trial Investigators","year":"2019","journal-title":"N Engl J Med"},{"key":"pone.0229469.ref007","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/CCO.0000000000000395","article-title":"Elderly patients with multiple myeloma: towards a frailty approach?","volume":"29","author":"EHA SWG on \u2018Aging and Hematology\u2019","year":"2017","journal-title":"Current Opinion in Oncology"},{"key":"pone.0229469.ref008","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"M Delforge","year":"2015","journal-title":"Haematologica"},{"key":"pone.0229469.ref009","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00520-012-1548-y","article-title":"Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey","volume":"21","author":"S Acaster","year":"2013","journal-title":"Supportive Care in Cancer"},{"key":"pone.0229469.ref010","unstructured":"National Institute for Health and Care Excellence. Lenalidomide plus dexamethasone for previously untreated multiple myeloma. Available from: https:\/\/www.nice.org.uk\/guidance\/TA587. Accessed August 31, 2019"},{"key":"pone.0229469.ref011","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"K. Yong","year":"2016","journal-title":"British Journal of Haematology"},{"key":"pone.0229469.ref012","first-page":"1","article-title":"Evaluating patients' preferences for multiple myeloma therapy, a Discrete-Choice-Experiment","volume":"5","author":"A.C M\u00fchlbacher","year":"2018","journal-title":"Psychosocial Medicine; 2008"},{"key":"pone.0229469.ref013","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/17474086.2017.1369399","article-title":"Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent","volume":"10","author":"P Richardson","year":"2017","journal-title":"Expert Reviews in Hematology"},{"key":"pone.0229469.ref014","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"VISTA Trial Investigators","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"pone.0229469.ref015","article-title":"Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy","author":"M.A Dimopoulos","year":"2014","journal-title":"Blood"},{"key":"pone.0229469.ref016","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/10428194.2015.1041386","article-title":"Clinical features and treatment outcome of very elderly patients over 80 years old with multiple myeloma: comparison with patients in different age groups in the era of novel agents","volume":"57","author":"K Matsue","year":"2016","journal-title":"Leukemia and Lymphoma"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0229469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T13:57:48Z","timestamp":1582293468000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0229469"}},"subtitle":[],"editor":[{"given":"Francesco","family":"Bertolini","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0229469","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2020,2,21]]}}}